LLY Stock: Eli Lilly and Company Stock Price, Analysis & Insights
Get live lly stock price $1021.70, comprehensive Eli Lilly and Company stock analysis, charts, news, and expert forecast. Real-time lly stock data and investment insights.
Loading chart...
Company Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Company Information
- CEO
- David A. Ricks
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 47000
Contact Information
- Website
- https://www.lilly.com
- Address
- Lilly Corporate Center
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Market leader with 917.8 billion market capitalization
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 50.1)
✓ Lower volatility stock (Beta: 0.39) may provide portfolio stability
Business Model & Strategy
Eli Lilly and Company operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a large-cap company, Eli Lilly and Company benefits from scale advantages, market presence, and established operations. Under the leadership of CEO David A. Ricks, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Eli Lilly and Company competes in the Drug Manufacturers - General within the broader Healthcare. With 917.8 billion in market capitalization, the company is positioned as a market leader in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Eli Lilly and Company provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Eli Lilly and Company should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Eli Lilly and Company shareholders
- ⚠Market volatility can significantly impact stock price, especially for large-cap equities
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Eli Lilly and Company
- ⚠Investors should consider how Eli Lilly and Company fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 50.1) requires strong growth to justify
Market Cap
917.78B
P/E Ratio
50.08
Beta
0.39
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 917.78B market capitalization
- Trading Volume: 3.37M shares traded today
- Price Range: 52-week range of $623.78 - $1033.62
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Eli Lilly and Company
Eli Lilly and Company (LLY) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 917.78B, the company represents a significant player in its market. The stock is currently trading at $1021.70 with a negativedaily change of 0.35%.
The company's 47000 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 50.08, beta of 0.39, and 52-week price range from $623.78 to $1033.62when evaluating investment opportunities.
Why Invest in Eli Lilly and Company?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under David A. Ricks
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.